Subject(s)
COVID-19 , Humans , Athletes , Magnetic Resonance Imaging, Cine , Magnetic Resonance ImagingSubject(s)
COVID-19 , Cardiology , Catheter Ablation , COVID-19/epidemiology , Greece/epidemiology , Humans , Pandemics , RegistriesSubject(s)
Betacoronavirus/immunology , Coronavirus Infections/complications , Disseminated Intravascular Coagulation/complications , Pneumonia, Viral/complications , Professional Role , Pulmonary Embolism/therapy , Surgeons , Anticoagulants/administration & dosage , COVID-19 , Catheters , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Coronavirus Infections/virology , Disseminated Intravascular Coagulation/immunology , Disseminated Intravascular Coagulation/virology , Humans , Mechanical Thrombolysis/instrumentation , Mechanical Thrombolysis/methods , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/virology , Pulmonary Embolism/diagnosis , Pulmonary Embolism/virology , SARS-CoV-2 , Severity of Illness IndexABSTRACT
OBJECTIVE: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention. METHODS: Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group. RESULTS: Trial results will be disseminated through peer-reviewed publications and conference presentations. CONCLUSION: GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (ClinicalTrials.gov Identifier: NCT04326790).